Ethics approval and consent to participate
The study was permitted by the Law of the People’s Republic of China on
the Protection of Wildlife, and the protocol was approved by the
Institutional Animal Care Committee of Shanghai University of medicine
& Health Sciences, China (Permit Number: JCLW01-08).
References:
- Frangogiannis NG. Cardiac fibrosis: Cell biological mechanisms,
molecular pathways and therapeutic opportunities. Mol Aspects Med.
2019;65:70-99.
- Blythe NM, Muraki K, Ludlow MJ, et al. Mechanically activated Piezo1
channels of cardiac fibroblasts stimulate p38 mitogen-activated
protein kinase activity and interleukin-6 secretion. J Biol Chem.
2019; 294(46): 17395-17408.
- Cook SA, Schafer S. Hiding in Plain Sight: Interleukin-11 Emerges as a
Master Regulator of Fibrosis, Tissue Integrity, and Stromal
Inflammation.Annu Rev Med. 2020 Jan 27;71:263-276.
[5] Rios FJ, Zou ZG, Harvey AP, et al. Chanzyme TRPM7 protects
against cardiovascular inflammation and fibrosis. Cardiovasc Res.
20201; 116(3): 721-735.
[6] Jung M, Ma Y, Iyer RP, et al. IL-10 improves cardiac
remodeling after myocardial infarction by stimulating M2 macrophage
polarization and fibroblast activation. Basic Res Cardiol. 2017;
112(3): 33:1-24.
[7] Pseftogas A, Gonidas C, Mosialos G. Activation of peroxisome
proliferator-activated receptor gamma in mammary epithelial cells
upregulates the expression of tumor suppressor Cyld to mediate growth
inhibition and anti-inflammatory effects. Int J Biochem Cell Biol.
2017; 82: 49-56.
[8] Thangaiyan R, Arjunan S, Govindasamy K,et al. Galangin
Attenuates Isoproterenol-Induced Inflammation and Fibrosis in the
Cardiac Tissue of Albino Wistar Rats. Front Pharmacol. 2020; 30;11:
585163.
[9] Kökény G, Calvier L, Legchenko E, et al. PPARgamma is a
gatekeeper for extracellular matrix and vascular cell homeostasis:
beneficial role in pulmonary hypertension and renal/cardiac/pulmonary
fibrosis. Curr Opin Nephrol Hypertens. 2020; 29(2): 171-179.
[10] Ghosh RK, Banerjee K, Tummala R, et al. Serelaxin in acute
heart failure: Most recent update on clinical and preclinical
evidence. Cardiovasc Ther. 2017; 35(1): 55-63.
[11] Tan J, Tedrow JR, Dutta JA, et al. Expression of RXFP1 Is
Decreased in Idiopathic Pulmonary Fibrosis. Implications for
Relaxin-based Therapies. Am J Respir Crit Care Med. 2016; 194(11):
1392-1402.
[12]Wang C, Pinar AA, Widdop RE, et al.The anti-fibrotic actions
of relaxin are mediated through AT(2) R-associated protein
phosphatases via RXFP1-AT(2) R functional crosstalk in human cardiac
myofibroblasts. FASEB J. 2020; 34(6): 8217-8233.
[13] Pinar AA, Yuferov A, Gaspari TA, et al. Relaxin Can Mediate
Its Anti-Fibrotic Effects by Targeting the Myofibroblast NLRP3
Inflammasome at the Level of Caspase-1. Front Pharmacol. 2020; 11:
1201
[14] Bennett RG, Simpson RL, Hamel FG. Serelaxin increases the
antifibrotic action of rosiglitazone in a model of hepatic fibrosis.
World J Gastroenterol. 2017; 23(22): 3999-4006.
- Bolívar S, Anfossi R, Humeres C, et al. IFN-beta Plays Both Pro- and
Anti-inflammatory Roles in the Rat Cardiac Fibroblast Through
Differential STAT Protein Activation. Front Pharmacol. 2018; 9: 1368.
- Emming S, Bianchi N, Polletti S, et al.A molecular network regulating
the proinflammatory phenotype of human memory T lymphocytes. Nat
Immunol. 2020; 21(4): 388-399.
- Felisbino MB, McKinsey TA. Epigenetics in Cardiac Fibrosis: Emphasis
on Inflammation and Fibroblast Activation. JACC Basic Transl Sci.
2018; 12;3(5):704-715.
- Sager HB, Heidt T, Hulsmans M, Dutta P, Courties G, Sebas M, et al.
Targeting interleukin-1beta reduces leukocyte production after acute
myocardial infarction. Circulation. (2015) 132:1880–1890.
- Abbate A, Trankle CR, Buckley LF, et al. Interleukin-1 Blockade
Inhibits the Acute Inflammatory Response in Patients With
ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc. 2020;
9(5):e014941.
[20] Scott L Jr, Li N, Dobrev D. Role of inflammatory signaling in
atrial fibrillation. Int J Cardiol. 2019; 287:195-200.
[21]Bansal SS, Ismahil MA, Goel M, et al. Dysfunctional and
Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse
Cardiac Remodeling in Ischemic Cardiomyopathy. Circulation.
2019;139(2):206-221.
[22] Zhao L, Cheng G, Jin R, et al. Deletion of Interleukin-6
Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and
Dysfunction. Circ Res. 2016;118(12):1918-1929.
[23]Collino M, Rogazzo M, Pini A, et al. Acute treatment with
relaxin protects the kidney against ischaemia/reperfusion injury. J Cell
Mol Med. 2013;17(11): 1494-505.
[24]Heo YJ, Choi SE, Jeon JY, et al. Visfatin Induces Inflammation
and Insulin Resistance via the NF-kappaB and STAT3 Signaling Pathways in
Hepatocytes. J Diabetes Res. 2019; 2019: 4021623.
[25] Ranjan P, Kumari R, Verma SK. Cardiac Fibroblasts and Cardiac
Fibrosis: Precise Role of Exosomes. Front Cell Dev Biol. 2019;7:318.
[26] Jung M, Ma Y, Iyer RP,et al. IL-10 improves cardiac remodeling
after myocardial infarction by stimulating M2 macrophage polarization
and fibroblast activation.Basic Res Cardiol. 2017 May;112(3):33
[27] Lee AS, Jung YJ, Thanh TN, et al. Paricalcitol attenuates
lipopolysaccharide-induced myocardial inflammation by regulating the
NF-kappaB signaling pathway. Int J Mol Med. 2016;37(4):1023-9.
[28] Vetuschi A, Pompili S, Gaudio E, et al. PPAR-gamma with its
anti-inflammatory and anti-fibrotic action could be an effective
therapeutic target in IBD. Eur Rev Med Pharmacol Sci. 2018; 22(24):
8839-8848.
[29] Bennett RG, Simpson RL,Hamel FG Serelaxin increases the
antifibrotic action of rosiglitazone in a model of hepatic fibrosis.
World J Gastroenterol.. 2017; 23(22): 3999-4006.
[30] Elkahloun AG, Rodriguez Y, Alaiyed S, et al. Telmisartan
Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor
Blockade or PPARgamma Activation. Mol Neurobiol. 2019;56(5):3193-3210.
[31] Zhang Y.-F., Zou X.-L., Wu J., Yu X.-Q., Yang X. Rosiglitazone,
a Peroxisome Proliferator-Activated Receptor (PPAR)-gamma Agonist,
Attenuates Inflammation Via NF-kappa B Inhibition in
Lipopolysaccharide-Induced Peritonitis. Inflammation.
2015;38(6):2105–2115.
Legend